Liu ZY, Zhou Y, Zhao FH, Wang L, Pan TJ, Gao L. New breakthroughs and future trends in renal cell carcinoma therapy: Highlights from the 2025 European Society for Medical Oncology Annual Congress. World J Clin Oncol 2026; 17(4): 118954 [DOI: 10.5306/wjco.v17.i4.118954]
Corresponding Author of This Article
Lei Gao, Professor, Department of Urology, General Hospital of Central Theater Command of Chinese People’s Liberation Army, Wuluo Road, Zhongnan Street, Wuhan 430070, Hubei Province, China. 511376424@qq.com
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Apr 24, 2026 (publication date) through Apr 22, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Liu ZY, Zhou Y, Zhao FH, Wang L, Pan TJ, Gao L. New breakthroughs and future trends in renal cell carcinoma therapy: Highlights from the 2025 European Society for Medical Oncology Annual Congress. World J Clin Oncol 2026; 17(4): 118954 [DOI: 10.5306/wjco.v17.i4.118954]
World J Clin Oncol. Apr 24, 2026; 17(4): 118954 Published online Apr 24, 2026. doi: 10.5306/wjco.v17.i4.118954
New breakthroughs and future trends in renal cell carcinoma therapy: Highlights from the 2025 European Society for Medical Oncology Annual Congress
Zhen-Yu Liu, Yu Zhou, Fu-Han Zhao, Lin Wang, Tie-Jun Pan, Lei Gao
Zhen-Yu Liu, Yu Zhou, Fu-Han Zhao, Lin Wang, Tie-Jun Pan, Lei Gao, Department of Urology, General Hospital of Central Theater Command of Chinese People’s Liberation Army, Wuhan 430070, Hubei Province, China
Co-first authors: Zhen-Yu Liu and Yu Zhou.
Co-corresponding authors: Tie-Jun Pan and Lei Gao.
Author contributions: Liu ZY and Zhou Y performed the original draft; Zhao FH and Wang L performed the edition of the draft; Gao L and Pan TJ designed the outline and coordinated the writing of the paper; Liu ZY and Zhou Y contributed equally to this manuscript as co-first authors; Gao L and Pan TJ are co-corresponding authors. All authors have read and approved the final version to be published.
Supported by the Natural Science Foundation of Hubei Province, No. 2023AFB498; Natural Science Foundation Exploration Plan (Morning Light Plan) of Wuhan City, No. 2024040801020363; and Postdoctoral Scientific Research Foundation, General Hospital of Central Theater Command, No. 20230102KY39.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Lei Gao, Professor, Department of Urology, General Hospital of Central Theater Command of Chinese People’s Liberation Army, Wuluo Road, Zhongnan Street, Wuhan 430070, Hubei Province, China. 511376424@qq.com
Received: January 16, 2026 Revised: January 29, 2026 Accepted: March 6, 2026 Published online: April 24, 2026 Processing time: 96 Days and 17.8 Hours
Core Tip
Core Tip: This timely review synthesizes pivotal advances in renal cell carcinoma management presented at the 2025 European Society for Medical Oncology Annual Congress. It highlights the shift towards precision medicine, evidenced by risk-stratified adjuvant immune checkpoint inhibitor therapy, promising short-course neoadjuvant immune checkpoint inhibitor strategies, and the evolution towards triple-combination regimens in advanced disease. A parallel focus is the critical development of predictive biomarkers—from molecular classifiers to artificial intelligence-based pathology tools—to guide individualized treatment selection and optimize outcomes across the disease spectrum, marking a decisive move beyond a one-size-fits-all therapeutic approach.
